⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

June 9, 2026Neurology

Real-world Healthcare Resource Utilization Following Initiation of Subcutaneous IgPro20 Among U.S. Patients With Chronic Inflammatory Demyelinating Polyneuropathy (P7-9.017)

Batyrkhan Kuatov Shicheng Weng Laurence Undreiner Aisara Chansakul Elizabeth Dabrowski Ann Madsen

View Full Paper

Ask AI

Bookmark

Share

Key Points

To characterize healthcare resource utilization (HCRU) among patients with chronic inflammatory demyelinating polyneuropathy (CIDP) who start subcutaneous IgPro20.
Analysis of healthcare resource utilization data post-initiation of subcutaneous IgPro20.
Focus on U.S. patients diagnosed with CIDP.
Increased healthcare resource utilization observed after initiating IgPro20 treatment.
Specific metrics of healthcare utilization and cost implications were highlighted.

Implication

Characterization of healthcare resource utilization after starting IgPro20 treatment in U.S. CIDP patients, suggesting important cost considerations.

Abstract

Characterize HCRU among CIDP patients who initiate subcutaneous IgPro20 (Immune Globulin [Human], 20% Liquid).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kuatov et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf403faef96ed7f0566f2 https://doi.org/10.1212/wnl.0000000000213144

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Real‐world safety and treatment patterns of subcutaneous <scp>IgPro20</scp> for chronic inflammatory demyelinating polyneuropathy: Post‐marketing surveillance in Japan2024
2Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trialRCT · 2017 · 281 citations
3Physician Insights on Transitioning Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Intravenous Immunoglobulin to Subcutaneous Efgartigimod PH20 (P7-9.016)Original Research · 2026 · 1 citations
4Patient-reported Outcomes with Hyaluronidase-facilitated Subcutaneous Immunoglobulin 10% Maintenance Therapy for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (P9-11.002)2024
5Multi-Indication Budget Impact Analysis of Subcutaneous IgPro20 Pre-filled Syringes for the Treatment of Primary Immunodeficiency Syndromes, Secondary Immunodeficiencies, and Chronic Inflammatory Demyelinating Polyneuropathy in ItalyOriginal Research · 2026